BB Biotech AG (LSE:0JYO) ROCE % : 0.00% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is BB Biotech AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BB Biotech AG's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.

BB Biotech AG ROCE % Historical Data

The historical data trend for BB Biotech AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG ROCE % Chart

BB Biotech AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

BB Biotech AG Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Dec17	Dec18	Dec19	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

BB Biotech AG ROCE % Calculation

BB Biotech AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	0	/	( ( (3094.031 - 3.13)	+	(2796.335 - 8.08) )	/ 2 )
	=	0	/	( (3090.901	+	2788.255)	/ 2 )
	=	0	/	2939.578
	=	0.00 %

BB Biotech AG's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	0	/	( ( (2796.335 - 8.08)	+	(2927.944 - 5.916) )	/ 2 )
	=	0	/	( ( 2788.255	+	2922.028 )	/ 2 )
	=	0	/	2855.1415
	=	0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

BB Biotech AG (LSE:0JYO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BB Biotech AG ROCE % Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BB Biotech AG (LSE:0JYO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (LSE:0JYO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BIONz:UK BBZA:Germany BION:Switzerland

Address

Schwertstrasse 6, Schaffhausen, CHE, CH-8200

Website

https://www.bbbiotech.com

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (LSE:0JYO) Headlines

No Headlines